Abstract: The present invention provides chalcone derivatives of the general formulae: ##STR1## wherein R.sub.1 is a hydroxyl, carboxylic or sulphonic acid group or a carboxyalkoxy or sulphoalkoxy radical, R.sub.2 is an unsaturated, straight-chained or branched aliphatic hydrocarbonyloxy radical, R.sub.3 is a hydrogen atom, a hydroxyl group or an alkoxy radical, R.sub.4 is an alkyl, hydroxyalkyl, alkoxy, carboxyalkoxy, sulphoalkoxy or carboxyalkylcarbonyloxyalkyl radical or a carboxylic acid or sulphonic acid group and R.sub.5 is a hydrogen or halogen atom, with the proviso that compounds of general formula (IIa) always contain at least one carboxylic or sulphonic acid group; and the nontoxic inorganic and organic salts of those compounds containing at least one carboxylic acid or sulphonic acid group.The present invention also provides a process for the preparation of these chalcone derivatives, as well as pharmaceutical compositions containing them.

Abstract: The present invention provides a pharmaceutical composition in the form of a water-containing cream which contains at least one glycyrrhetinic acid derivative (as hereinbefore defined), together with at least one non-toxic, water-soluble salt of zinc, calcium and/or magnesium as stabilizer.

Abstract: The present invention provides 1,2-diphenylethane derivatives of the general formula: ##STR1## wherein X is a hydrogen or halogen atom, R and R', which may be the same or different, are alkyl radicals optionally substituted by halogen atoms, R.sub.1 and R.sub.2, which may be the same or different, are acyl radicals, hydroxyl groups or acylated hydroxyl groups and R.sub.3 and R.sub.4, which may be the same or different, are hydroxyl groups or acylated or alkylated hydroxyl groups.The present invention also provides processes for the preparation of these compounds and pharmaceutical compositions containing them.

Abstract: The present invention provides a pharmaceutical composition for treating ulcerative colitis containing at least one compound of the general formula: ##STR1## wherein X is an --SO.sub.2 -- or --CO-- group and R is either an unsubstituted or substituted non-heterocyclic aromatic ring system or is a radical of the general formula --(CH.sub.2).sub.n --Y, in which Y is a hydroxyl group, an unsubstituted or substituted amino group or a carboxylic or sulphonic acid group and n is a whole number of from 1 to 6 and in which one or more hydrogen atoms in the alkylene radical can be replaced by unsubstituted or substituted amino groups or alkyl radicals and in which the --(CH.sub.2).sub.n --Y radical is either attached directly to the nitrogen atom or via a benzene ring; and/or containing at least one ester thereof and/or at least one non-toxic, pharmaceutically acceptable salt thereof, in admixture with a solid or liquid pharmaceutical diluent or carrier.

Abstract: The present invention provides an enzyme which is an odorless, white powder, the pH of a 15000 to 22000 IU/ml. solution of which in carbon dioxide-free physiological saline solution suitable for injection is 4.5 to 7.5, the solution being clear and colorless; a solution of 50000 IU of which in 3 ml. carbon dioxide-free physiological saline solution suitable for injection has a light absorption of not more than 0.60 at 280 nm and of not more than 0.37 at 260 nm; the enzyme having the following percentage amino acid analysis:______________________________________ Asp 11.1 .+-. 0.4; Thr 5.8 .+-. 0.1; Ser 6.4 .+-. 0.2; Glu 9.1 .+-. 0.2; Pro 5.0 .+-. 0.5; Gly 6.6 .+-. 0.2; Ala 7.4 .+-. 0.1; Val 7.9 .+-. 0.5; Met 0.8 .+-. 0.1; Ile 5.2 .+-. 0.2; Leu 10.9 .+-. 0.2; Tyr 4.4 .+-. 0.1; Phe 4.5 .+-. 0.1; His 2.8 .+-. 0.2; Lys 7.6 .+-. 0.4; Arg 5.6 .+-. 0.1; ______________________________________said enzyme having a total hexose content of 10.6.+-.0.003%; said enzyme containing not more than 5 .mu.g.

Abstract: The present invention provides a water-soluble or water-dispersible particulate pharmaceutical composition comprising, per one part by weight of glycyrrhetinic acid and/or glycyrrhetinic acid derivative (as hereinbefore defined), 10 to 100 parts by weight of lactose and/or sorbitol, 10 to 50 parts by weight of at least one buffer selected from sodium citrate, potassium citrate, sodium tartrate, potassium tartrate, sodium malate and potassium malate and 0.1 to 10 parts by weight of disodium edetate.

Abstract: The present invention provides new chalcone derivatives of the general formula: ##STR1## wherein R.sub.1 is a hydroxyl, carboxylic acid or sulphonic acid group or a carboxyalkoxy or sulphoalkoxy radical, R.sub.2 and R.sub.3, which may be the same or different, are hydrogen or halogen atoms, hydroxyl groups or alkoxy radicals and R.sub.4 is an alkyl, hydroxyalkyl, alkoxy, carboxyalkoxy, sulphoalkoxy or carboxyalkylcarbonyloxyalkyl radical or a carboxylic acid or sulphonic acid group, with the proviso that compounds of general formula (Ia) always contain at least one carboxylic acid or sulphonic acid group; and the non-toxic inorganic and organic salts of those compounds containing at least one carboxylic acid or sulphonic acid group, the compounds of the invention are useful for treating inflammatory and allergic conditions and for treating ulcerous conditions of the gastro-intestinal tract in humans.

Abstract: The present invention is concerned with a process for the preparation of very pure and highly active glucuronoglycosaminoglycan hyaluronate lyase by means of a special chromatographic process.

Abstract: The present invention provides new glycyrrhetinic acid derivatives of the general formula: ##STR1## wherein R is an alkylene or cycloalkylene radical and X represents an oxygen atom or two hydrogen atoms; and the non-toxic salts and esters thereof.

Abstract: There is provided a new derivative of 1,2-diphenyl-ethane of the formula:- ##STR1## This new compound has been found to be very useful for the treatment of hypertrophied conditions of the prostate.

Abstract: The present invention provides new and pharmaceutically useful amides of the general formula: ##STR1## wherein X is the acyl residue of 18.alpha.- or 18.beta.-glycyrrhetinic acid, the 3-hydroxyl group of which can be acylated with a mono-, di- or polybasic inorganic or organic acid, or X is the acyl residue of 3-keto-18.alpha.- or -18.beta.-glycyrrhetinic acid; and the metoclopramide salts of those compounds containing at least one free carboxylic acid group.

Abstract: The present invention is concerned with new derivatives of erythrodiol of the general formula: ##STR1## wherein R' is a hydrogen atom or an acyl radical derived from a mono- or polycarboxylic acid and R is a radical derived from a monocarboxylic acid containing 3 or more carbon atoms or from a polycarboxylic acid, any carboxylic acid groups therein being in the free form or in the salt form.

Abstract: The present invention provides new 1,2-diphenyl-ethane derivatives of the general formula: ##SPC1##Wherein R is a hydrogen atom or an alkyl or acyl radical, X is a hydrogen or halogen atom and R' is an alkyl radical.

Abstract: There is provided a pharmaceutical composition in dosage unit form comprising (a) 1 - 100 mg. of glycyrrhetinic acid and/or of at least one anti-inflammatory active derivative thereof, in admixture with (b) 1 - 50% by weight of alginic acid and/or at least one non-toxic salt thereof and/or of at least one carboxyalkyl-cellulose and/or of at least one non-toxic salt thereof, (c) 1 - 30% by weight of at least one non-toxic carbonate and/or bicarbonate and (d) 0 - 30% by weight of at least one antacid compound.

Abstract: The present invention provides chalcone derivatives of the general formulae: ##STR1## wherein R.sub.1 is a hydroxyl, carboxylic or sulphonic acid group or a carboxyalkoxy or sulphoalkoxy radical, R.sub.2 is an unsaturated, straight-chained or branched aliphatic hydroxycarbonyloxy radical, R.sub.3 is a hydrogen atom, a hydroxyl group or an alkoxy radical, R.sub.4 is an alkyl, hydroxyalkyl, alkoxy, carboxyalkoxy, sulphoalkoxy or carboxyalkylcarbonyloxyalkyl radical or a carboxylic acid or sulphonic acid group and R.sub.5 is a hydrogen or halogen atom, with the proviso that compounds of general formula (IIa) always contain at least one carboxylic or sulphonic acid group; and the nontoxic inorganic and organic salts of those compounds containing at least one carboxylic acid or sulphonic acid group.The present invention also provides a process for the preparation of these chalcone derivatives, as well as pharmaceutical compositions containing them.